News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis Six factors shaping healthcare in emerging markets The factors shaping the healthcare landscape in emerging markets.
Views & Analysis UK pharma denied legal challenge to drugs bill cap - updated Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
